Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Viread

Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8

HOS-110475 · Präparat HOS-093385

Concomitant use not recommended Viread should not be administered concomitantly with other medicinal products containing tenofovir disoproxil or tenofovir alafenamide.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir alafenamide (HOS-110476)

Wechselwirkungen · Viread

Viread 163 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 47

HOS-110583 · Präparat HOS-093385

Concomitant use not recommended Viread should not be administered concomitantly with other medicinal products containing tenofovir disoproxil or tenofovir alafenamide.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir alafenamide (HOS-110476)

Wechselwirkungen · Viread

Viread 204 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 87

HOS-110674 · Präparat HOS-093385

Concomitant use not recommended Viread should not be administered concomitantly with other medicinal products containing tenofovir disoproxil or tenofovir alafenamide.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir alafenamide (HOS-110476)

Wechselwirkungen · Viread

Viread 245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 129

HOS-110764 · Präparat HOS-093385

Concomitant use not recommended Viread should not be administered concomitantly with other medicinal products containing tenofovir disoproxil or tenofovir alafenamide.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir alafenamide (HOS-110476)

Wechselwirkungen · Viread

Viread 33 mg/g granules · Abschnitt 4.5 · PDF-Seite 172

HOS-110855 · Präparat HOS-093385

Concomitant use not recommended Viread should not be administered concomitantly with other medicinal products containing tenofovir disoproxil or tenofovir alafenamide.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir alafenamide (HOS-110476)

Wechselwirkungen · Truvada

Truvada 200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10

HOS-113713 · Präparat HOS-093961

Truvada should not be administered concomitantly with other medicinal products containing emtricitabine, tenofovir disoproxil, tenofovir alafenamide or other cytidine analogues, such as lamivudine (see section 4.4). Truvada should not be administered concomitantly with adefovir dipivoxil.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): adefovir dipivoxil (HOS-110478) tenofovir alafenamide (HOS-110476) lamivudine (HOS-085829)

Wechselwirkungen · Prezista

PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 11–12

HOS-116342 · Präparat HOS-094447

11  Raltegravir Some clinical studies suggest raltegravir At present the effect of raltegravir may cause a modest decrease in on darunavir plasma darunavir plasma concentrations. concentrations does not appear to be clinically relevant. Boosted PREZISTA and raltegravir can be used without dose adjustments. Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs) Didanosine didanosine AUC ↓ 9% Boosted PREZISTA and 400 mg once daily didanosine Cmin ND didanosine can be used without didanosine Cmax ↓ 16% dose adjustments. darunavir AUC ↔ Didanosine is to be administered darunavir Cmin ↔ on an empty stomach, thus it darunavir Cmax ↔ should be administered 1 hour before or 2 hours after boosted PREZISTA given with food. Tenofovir disoproxil tenofovir AUC ↑ 22% Monitoring of renal function may 245 mg once daily‡ tenofovir Cmin ↑ 37% be indicated when boosted tenofovir Cmax ↑ 24% PREZISTA is given in # darunavir AUC ↑ 21% combination with tenofovir # darunavir Cmin ↑ 24% disoproxil, particularly in patients # with underlying systemic or renal darunavir Cmax ↑ 16% disease, or in patients taking (↑ tenofovir from effect on MDR-1 nephrotoxic agents. transport in the renal tubules) PREZISTA co-administered with cobicistat lowers the creatinine clearance. Refer to section 4.4 if creatinine clearance is used for dose adjustment of tenofovir disoproxil. Emtricitabine/tenofovir Tenofovir alafenamide ↔ The recommended dose of alafenamide Tenofovir ↑ emtricitabine/tenofovir alafenamide is 200/10 mg once daily when used with boosted PREZISTA. Abacavir Not studied. Based on the different Boosted PREZISTA can be used Emtricitabine elimination pathways of the other NRTIs with these NRTIs without dose Lamivudine zidovudine, emtricitabine, stavudine, adjustment. Stavudine lamivudine, that are primarily renally Zidovudine excreted, and abacavir for which PREZISTA co-administered with metabolism is not mediated by CYP450, cobicistat lowers the creatinine no interactions are expected for these clearance. Refer to section 4.4 if medicinal compounds and boosted creatinine clearance is used for PREZISTA. dose adjustment of emtricitabine or lamivudine.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir alafenamide (HOS-110476) stavudine (HOS-088080) cobicistat (HOS-088111) creatinine (HOS-086273) tenofovir disoproxil (HOS-108843) lamivudine (HOS-085829) didanosine (HOS-085836) zidovudine (HOS-085837) raltegravir (HOS-086187) abacavir (HOS-088077) emtricitabine (HOS-085840)

Wechselwirkungen · Prezista

PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53–54

HOS-116511 · Präparat HOS-094447

53 Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs) Didanosine didanosine AUC ↓ 9% PREZISTA co-administered with 400 mg once daily didanosine Cmin ND low dose ritonavir and didanosine didanosine Cmax ↓ 16% can be used without dose darunavir AUC ↔ adjustments. darunavir Cmin ↔ Didanosine is to be administered darunavir Cmax ↔ on an empty stomach, thus it should be administered 1 hour before or 2 hours after PREZISTA/ritonavir given with food. Tenofovir disoproxil tenofovir AUC ↑ 22% Monitoring of renal function may 245 mg once daily‡ tenofovir Cmin ↑ 37% be indicated when PREZISTA tenofovir Cmax ↑ 24% co-administered with low dose # darunavir AUC ↑ 21% ritonavir is given in combination # darunavir Cmin ↑ 24% with tenofovir disoproxil, # particularly in patients with darunavir Cmax ↑ 16% underlying systemic or renal (↑ tenofovir from effect on MDR-1 disease, or in patients taking transport in the renal tubules) nephrotoxic agents. Emtricitabine/tenofovir Tenofovir alafenamide ↔ The recommended dose of alafenamide Tenofovir ↑ emtricitabine/tenofovir alafenamide is 200/10 mg once daily when used with PREZISTA with low dose ritonavir. Abacavir Not studied. Based on the different PREZISTA co-administered with Emtricitabine elimination pathways of the other NRTIs low dose ritonavir can be used Lamivudine zidovudine, emtricitabine, stavudine, with these NRTIs without dose Stavudine lamivudine, that are primarily renally adjustment. Zidovudine excreted, and abacavir for which metabolism is not mediated by CYP450, no interactions are expected for these medicinal compounds and PREZISTA co-administered with low dose ritonavir. Non-nucleo(s/t)ide reverse transcriptase inhibitors (NNRTIs) Efavirenz efavirenz AUC ↑ 21% Clinical monitoring for central 600 mg once daily efavirenz Cmin ↑ 17% nervous system toxicity associated efavirenz Cmax ↑ 15% with increased exposure to # darunavir AUC ↓ 13% efavirenz may be indicated when # darunavir Cmin ↓ 31% PREZISTA co-administered with # low dose ritonavir is given in darunavir Cmax ↓ 15% combination with efavirenz. (↑ efavirenz from CYP3A inhibition) (↓ darunavir from CYP3A induction) Efavirenz in combination with PREZISTA/ritonavir 800/100 mg once daily may result in sub-optimal darunavir Cmin. If efavirenz is to be used in combination with PREZISTA/ritonavir, the PREZISTA/ritonavir 600/100 mg twice daily regimen should be used (see section 4.4). Etravirine etravirine AUC ↓ 37% PREZISTA co-administered with 100 mg twice daily etravirine Cmin ↓ 49% low dose ritonavir and etravirine etravirine Cmax ↓ 32% 200 mg twice daily can be used darunavir AUC ↑ 15% without dose adjustments. darunavir Cmin ↔ darunavir Cmax ↔

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir alafenamide (HOS-110476) stavudine (HOS-088080) etravirine (HOS-088088) tenofovir disoproxil (HOS-108843) lamivudine (HOS-085829) didanosine (HOS-085836) zidovudine (HOS-085837) efavirenz (HOS-087947) ritonavir (HOS-084521) abacavir (HOS-088077) emtricitabine (HOS-085840)

Wechselwirkungen · Prezista

PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 93–94

HOS-116603 · Präparat HOS-094447

93  Tenofovir disoproxil tenofovir AUC ↑ 22% Monitoring of renal function may 245 mg once daily‡ tenofovir Cmin ↑ 37% be indicated when boosted tenofovir Cmax ↑ 24% PREZISTA is given in # darunavir AUC ↑ 21% combination with tenofovir # darunavir Cmin ↑ 24% disoproxil, particularly in patients # with underlying systemic or renal darunavir Cmax ↑ 16% disease, or in patients taking (↑ tenofovir from effect on MDR-1 nephrotoxic agents. transport in the renal tubules) PREZISTA co-administered with cobicistat lowers the creatinine clearance. Refer to section 4.4 if creatinine clearance is used for dose adjustment of tenofovir disoproxil. Emtricitabine/tenofovir Tenofovir alafenamide ↔ The recommended dose of alafenamide Tenofovir ↑ emtricitabine/tenofovir alafenamide is 200/10 mg once daily when used with boosted PREZISTA. Abacavir Not studied. Based on the different Boosted PREZISTA can be used Emtricitabine elimination pathways of the other NRTIs with these NRTIs without dose Lamivudine zidovudine, emtricitabine, stavudine, adjustment. Stavudine lamivudine, that are primarily renally Zidovudine excreted, and abacavir for which PREZISTA co-administered with metabolism is not mediated by CYP450, cobicistat lowers the creatinine no interactions are expected for these clearance. Refer to section 4.4 if medicinal compounds and boosted creatinine clearance is used for PREZISTA. dose adjustment of emtricitabine or lamivudine. Non-nucleo(s/t)ide reverse transcriptase inhibitors (NNRTIs) Efavirenz efavirenz AUC ↑ 21% Clinical monitoring for central 600 mg once daily efavirenz Cmin ↑ 17% nervous system toxicity associated efavirenz Cmax ↑ 15% with increased exposure to # darunavir AUC ↓ 13% efavirenz may be indicated when # darunavir Cmin ↓ 31% PREZISTA co-administered with # low dose ritonavir is given in darunavir Cmax ↓ 15% combination with efavirenz. (↑ efavirenz from CYP3A inhibition) (↓ darunavir from CYP3A induction) Efavirenz in combination with PREZISTA/ritonavir 800/100 mg once daily may result in sub-optimal darunavir Cmin. If efavirenz is to be used in combination with PREZISTA/ritonavir, the PREZISTA/ritonavir 600/100 mg twice daily regimen should be used (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir alafenamide (HOS-110476) stavudine (HOS-088080) cobicistat (HOS-088111) creatinine (HOS-086273) tenofovir disoproxil (HOS-108843) lamivudine (HOS-085829) zidovudine (HOS-085837) efavirenz (HOS-087947) ritonavir (HOS-084521) abacavir (HOS-088077) emtricitabine (HOS-085840)

Wechselwirkungen · Eviplera

Eviplera 200 mg/25 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8

HOS-214355 · Präparat HOS-155326

Eviplera should not be administered concomitantly with other medicinal products containing emtricitabine, tenofovir disoproxil or tenofovir alafenamide. Eviplera should not be administered concomitantly with rilpivirine hydrochloride unless needed for dose adjustment with rifabutin (see section 4.2).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir alafenamide (HOS-110476) rifabutin (HOS-086262)

Wechselwirkungen · Eviplera

Eviplera 200 mg/25 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 20

HOS-214424 · Präparat HOS-155326

Rilpivirine: AUC: ↔ Vardenafil2 Cmin: ↔ Tadalafil2 Cmax: ↔ Sildenafil/Tenofovir disoproxil Interaction not studied. N/A = not applicable 1 This interaction study has been performed with a dose higher than the recommended dose for rilpivirine hydrochloride assessing the maximal effect on the co-administered medicinal product. The dosing recommendation is applicable to the recommended dose of rilpivirine of 25 mg once daily. 2 These are medicinal products within class where similar interactions could be predicted. 3 This interaction study has been performed with a dose higher than the recommended dose for rilpivirine hydrochloride assessing the maximal effect on the co-administered medicinal product. 4 The predominant circulating metabolite of sofosbuvir. 5 Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposures expected in hepatitis C virus (HCV) infected patients. 6 Study conducted with emtricitabine/rilpivirine/tenofovir alafenamide fixed-dose combination tablet.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) tenofovir alafenamide (HOS-110476) hepatitis C virus (HOS-108813) voxilaprevir (HOS-108930) sildenafil (HOS-086162)

Gegenanzeigen · Genvoya

Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4

HOS-133891 · Präparat HOS-097520

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Gegenanzeigen · Genvoya

Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4

HOS-133892 · Präparat HOS-097520

Co-administration with medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious or life-threatening adverse reactions. Therefore, Genvoya should not be co-administered with medicinal products that include, but are not limited to, the following (see sections 4.4 and 4.5): • alpha 1-adrenoreceptor antagonists: alfuzosin • antiarrhythmics: amiodarone, quinidine • ergot derivatives: dihydroergotamine, ergometrine, ergotamine • gastrointestinal motility agents: cisapride • HMG Co-A reductase inhibitors: lovastatin, simvastatin • lipid-modifying agent: lomitapide • neuroleptics/antipsychotics: pimozide, lurasidone • PDE-5 inhibitors: sildenafil for the treatment of pulmonary arterial hypertension • sedatives/hypnotics: orally administered midazolam, triazolam

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) cisapride (HOS-085610) lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) quinidine (HOS-085593) pimozide (HOS-085600) sildenafil (HOS-086162) ergotamine (HOS-086154) amiodarone (HOS-085596) lurasidone (HOS-086148) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)

Gegenanzeigen · Genvoya

Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4

HOS-133905 · Präparat HOS-097520

Co-administration with medicinal products that are strong inducers of CYP3A due to the potential for loss of virologic response and possible resistance to Genvoya. Therefore, Genvoya should not be co-administered with medicinal products that include, but are not limited to, the following (see sections 4.4 and 4.5): • anticonvulsants: carbamazepine, phenobarbital, phenytoin • antimycobacterials: rifampicin • herbal products: St. John’s wort (Hypericum perforatum)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) phenytoin (HOS-084531)

Gegenanzeigen · Genvoya

Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4

HOS-133906 · Präparat HOS-097520

Co-administration with dabigatran etexilate, a P-glycoprotein (P-gp) substrate (see section 4.5).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dabigatran etexilate (HOS-086233)

Wechselwirkungen · Genvoya

Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-133908 · Präparat HOS-097520

Genvoya should not be co-administered with other antiretroviral medicinal products. Therefore, information regarding drug-drug interactions with other antiretroviral products (including protease inhibitors [PIs] and non-nucleoside reverse transcriptase inhibitors [NNRTIs]) is not provided (see section 4.4). Interaction studies have only been performed in adults.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623)

Wechselwirkungen · Genvoya

Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-133909 · Präparat HOS-097520

Genvoya should not be administered concomitantly with medicinal products containing tenofovir alafenamide, tenofovir disoproxil, lamivudine or adefovir dipivoxil used for the treatment of HBV infection.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) adefovir dipivoxil (HOS-110478) tenofovir disoproxil (HOS-108843) lamivudine (HOS-085829)

Wechselwirkungen · Genvoya

Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-133914 · Präparat HOS-097520

Elvitegravir

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Genvoya

Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-133915 · Präparat HOS-097520

Elvitegravir is primarily metabolised by CYP3A, and medicinal products that induce or inhibit CYP3A may affect the exposure of elvitegravir. Co-administration of Genvoya with medicinal products that induce CYP3A may result in decreased plasma concentrations of elvitegravir and reduced therapeutic effect of Genvoya (see “Concomitant use contraindicated” and section 4.3). Elvitegravir may have the potential to induce CYP2C9 and/or inducible uridine diphosphate glucuronosyltransferase (UGT) enzymes; as such it may decrease the plasma concentration of substrates of these enzymes.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): uridine (HOS-085192)

Wechselwirkungen · Genvoya

Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-133917 · Präparat HOS-097520

Cobicistat

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.